Structure

InChI Key WIGIZIANZCJQQY-RUCARUNLSA-N
Smile CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O
InChI
InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

Physicochemical Descriptors

Property Name Value
Molecular Formula C24H34N4O5S
Molecular Weight 490.63
AlogP 3.07
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 7.0
Polar Surface Area 124.68
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 34.0

Pharmacology

Action Mechanism of Action Reference
BLOCKER Sulfonylurea receptor 1, Kir6.2 blocker PubMed PubMed PubMed DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Diabetes Mellitus 4 D003920 ClinicalTrials
Diabetes Mellitus, Type 2 4 D003924 ClinicalTrials
Hypertension 3 D006973 ClinicalTrials
Atherosclerosis 3 D050197 ClinicalTrials
Hypercholesterolemia 3 D006937 ClinicalTrials
Coronary Disease 3 D003327 ClinicalTrials

Related Entries

Scaffolds

Mixture
Mixture

Side Effects from Label

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Metabolism and nutrition disorders
13.56
Nervous system disorders
12.04
Endocrine disorders
10.68
Investigations
10.13
General disorders and administration site conditions
8.83
Gastrointestinal disorders
5.69
Psychiatric disorders
5.46
Injury, poisoning and procedural complications
5.36
Cardiac disorders
4.62
Vascular disorders
4.57
Skin and subcutaneous tissue disorders
3.15
Renal and urinary disorders
2.97
Respiratory, thoracic and mediastinal disorders
2.74
Musculoskeletal and connective tissue disorders
2.15

Cross References

Resources Reference
CAS NUMBER 93479-97-1
ChEBI 5383
ChEMBL CHEMBL1481
DrugBank DB00222
DrugCentral 1300
EPA CompTox DTXSID5040675
FDA SRS 6KY687524K
Guide to Pharmacology 6820
SureChEMBL SCHEMBL16086
ZINC ZINC000100070954